Published in Hepatitis Weekly, September 18th, 2000
Hybrigenics will select several potential drug targets using the PIMRider technology to define the specific protein domains involved in protein-protein interactions. XTL will biovalidate these targets and corresponding therapeutics for efficacy in treating HCV using its proprietary cell-based assays and Trimera (XTL) mouse model of HCV...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.